--- title: "FY2030 EPS Estimates for Palisade Bio Reduced by Analyst" type: "News" locale: "en" url: "https://longbridge.com/en/news/296061307.md" description: "Brookline Capital Markets lowered Palisade Bio's FY2030 EPS estimate to $0.39 from $0.41, citing a report on August 14. The company recently reported Q2 EPS of ($0.05), meeting expectations. Analyst ratings vary, with a consensus 'Buy' and average price target of $9.00. Institutional investors increased stakes in Q4, while insiders Robert Baltera bought shares and Mitchell Jones sold shares for tax obligations." datetime: "2026-08-17T05:57:47.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296061307.md) - [en](https://longbridge.com/en/news/296061307.md) - [zh-HK](https://longbridge.com/zh-HK/news/296061307.md) generator: "portal-rs" --- # FY2030 EPS Estimates for Palisade Bio Reduced by Analyst Palisade Bio, Inc. (NASDAQ:PALI - Free Report) - Equities research analysts at Brookline Capital Markets lowered their FY2030 earnings estimates for shares of Palisade Bio in a report issued on Friday, August 14th. Brookline Capital Markets analyst K. Raja now anticipates that the company will post earnings per share of $0.39 for the year, down from their prior estimate of $0.41. The consensus estimate for Palisade Bio's current full-year earnings is ($0.22) per share. Palisade Bio (NASDAQ:PALI - Get Free Report) last announced its earnings results on Monday, August 10th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.05). The firm had revenue of $0.50 million during the quarter, compared to analysts' expectations of $0.50 million. PALI has been the topic of several other research reports. Wall Street Zen upgraded Palisade Bio from a "sell" rating to a "hold" rating in a report on Saturday, July 25th. Weiss Ratings cut Palisade Bio from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday, July 14th. HC Wainwright reaffirmed a "buy" rating and issued a $2.00 target price on shares of Palisade Bio in a research report on Tuesday, June 30th. LADENBURG THALM/SH SH raised Palisade Bio to a "strong-buy" rating in a research report on Thursday, June 25th. Finally, Oppenheimer assumed coverage on shares of Palisade Bio in a research note on Thursday, July 23rd. They set an "outperform" rating and a $8.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Palisade Bio currently has a consensus rating of "Buy" and an average price target of $9.00. **Check Out Our Latest Stock Report on PALI** ## Palisade Bio Price Performance PALI opened at $2.14 on Monday. Palisade Bio has a 52 week low of $0.53 and a 52 week high of $2.86. The business has a fifty day simple moving average of $1.95 and a 200-day simple moving average of $1.91. The firm has a market cap of $372.94 million, a P/E ratio of -2.12 and a beta of 1.52. ## Institutional Investors Weigh In On Palisade Bio Several large investors have recently bought and sold shares of PALI. Cetera Investment Advisers acquired a new stake in Palisade Bio in the 4th quarter valued at about $25,000. Schonfeld Strategic Advisors LLC acquired a new position in shares of Palisade Bio during the fourth quarter worth about $26,000. Virtu Financial LLC purchased a new stake in shares of Palisade Bio during the fourth quarter worth approximately $28,000. Legal & General Group Plc purchased a new stake in shares of Palisade Bio during the second quarter worth approximately $30,000. Finally, CTC Alternative Strategies Ltd. acquired a new stake in Palisade Bio in the first quarter valued at approximately $31,000. Hedge funds and other institutional investors own 11.79% of the company's stock. ## Insider Transactions at Palisade Bio In related news, Director Robert Jr. Baltera acquired 25,000 shares of Palisade Bio stock in a transaction dated Thursday, July 9th. The shares were acquired at an average cost of $1.96 per share, for a total transaction of $49,000.00. Following the completion of the purchase, the director owned 461,904 shares in the company, valued at approximately $905,331.84. The trade was a 5.72% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Mitchell Lawrence Jones sold 51,880 shares of the stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $2.05, for a total value of $106,354.00. Following the completion of the sale, the insider owned 94,009 shares in the company, valued at approximately $192,718.45. The trade was a 35.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have purchased 125,000 shares of company stock valued at $250,100. 0.07% of the stock is currently owned by company insiders. ## Palisade Bio Company Profile (Get Free Report) Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity. The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors. ## Further Reading - Five stocks we like better than Palisade Bio - The Metals Company’s Big Bet Now Comes Down to a License - OneSpaWorld Keeps Turning Cruise Demand Into Record Earnings - Meta and Tesla Are Rebounding From Oversold Levels—Now What? - AMG’s Alternatives Boom Powers Record Growth *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in Palisade Bio Right Now? Before you consider Palisade Bio, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Palisade Bio wasn't on the list. While Palisade Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [PALI.US](https://longbridge.com/en/quote/PALI.US.md) - [OPY.US](https://longbridge.com/en/quote/OPY.US.md) - [VIRT.US](https://longbridge.com/en/quote/VIRT.US.md) - [LGEN.UK](https://longbridge.com/en/quote/LGEN.UK.md) ## Related News & Research - [Palisade Bio to join Wells Fargo, Morgan Stanley and H.C. Wainwright healthcare investor conferences](https://longbridge.com/en/news/297918838.md) - [Palisade Bio Q2 net loss widens on higher R&D costs](https://longbridge.com/en/news/295446808.md) - [Braveheart Bio, Inc.'s Quiet Period To Expire on September 15th (NASDAQ:BRVE)](https://longbridge.com/en/news/298264807.md) - [FY2028 EPS Estimates for Upstream Bio Decreased by Analyst](https://longbridge.com/en/news/298028139.md) - [Palisade Bio, Inc. (NASDAQ:PALI) Given Average Recommendation of "Buy" by Analysts](https://longbridge.com/en/news/293182118.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**